AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Rhea-AI Summary

AbbVie (NYSE: ABBV) reported nine-year Phase 3 CLL14 results for fixed-duration VENCLEXTA/VENCLYXTO (venetoclax) plus obinutuzumab in previously untreated chronic lymphocytic leukemia at EHA 2026.

The regimen showed median progression-free survival of 6.4 vs 3.2 years and median time to next treatment of 7.6 years, after one year of therapy.

Positive

• Median progression-free survival 6.4 vs 3.2 years; hazard ratio 0.50
• Median time to next treatment of 7.6 years after one-year regimen
• Nine-year follow-up demonstrates long-term off-treatment efficacy and safety
• Provides limited-duration first-line option for unfit CLL patients
• Results support venetoclax-based combinations in broader first-line CLL populations

Negative

• Grade 3+ adverse events included neutropenia and thrombocytopenia
• Additional Grade 3+ events: infusion reactions, anemia, febrile neutropenia, pneumonia, leukopenia

News Market Reaction – ABBV

+1.32%

+1.32% Session close to close

In the Jun 12 session, ABBV gained 1.32%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights nine-year results from the Phase 3 CLL14 trial, showing venetoclax plus...

Analysis

This announcement highlights nine-year results from the Phase 3 CLL14 trial, showing venetoclax plus obinutuzumab delivering a median PFS of 6.4 years and median time to next treatment of 7.6 years, with a PFS hazard ratio of 0.50 and p<0.001. In context of AbbVie’s recent blood cancer approvals and label expansions, investors may track how these durable outcomes influence treatment guidelines, real‑world adoption, safety profiles, and future regulatory or competitive developments in first-line CLL.

Key Figures

Median TTNT: 7.6 years Median follow-up: 9.2 years Median PFS (V+O): 6.4 years +3 more

6 metrics

Median TTNT 7.6 years Time to next treatment in Phase 3 CLL14 venetoclax + obinutuzumab arm

Median follow-up 9.2 years Follow-up duration in Phase 3 CLL14 trial

Median PFS (V+O) 6.4 years Progression-free survival with venetoclax + obinutuzumab in CLL14

Median PFS (O+C) 3.2 years Progression-free survival with obinutuzumab + chlorambucil in CLL14

Hazard ratio for PFS 0.50 (95% CI 0.39–0.63) Venetoclax + obinutuzumab vs obinutuzumab + chlorambucil in CLL14

P-value p<0.001 PFS comparison between treatment arms in CLL14

Historical Context

5 past events · Latest: Jun 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Aesthetics consumer report	Neutral	-0.2%	Allergan Aesthetics released a report on consumer motivations and expectations.
Jun 8	Blood cancer data	Positive	-0.7%	New EHA 2026 data across multiple blood cancers, including venetoclax and epcoritamab.
Jun 2	Conference appearance	Neutral	+1.2%	Management scheduled for a fireside chat at a major Goldman Sachs healthcare conference.
May 29	EU label expansion	Positive	-0.4%	European Commission authorized expanded VENCLYXTO label for additional first-line CLL combinations.
May 27	FDA approval	Positive	+1.5%	U.S. FDA approved DECNUPAZ for adult BPDCN based on CADENZA trial data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive regulatory and data milestones have produced mixed reactions, with several blood cancer wins not consistently translating into upside.

Recent Company History

Over the past few weeks, AbbVie has reported multiple oncology and corporate developments. A consumer-focused Allergan Aesthetics report on trends in aesthetic demand (Jun 10) and broad blood cancer data at EHA 2026 (Jun 8) were followed by modest share declines. Participation in the Goldman Sachs healthcare conference (Jun 2) coincided with a gain. A key EU label expansion for VENCLYXTO in first-line CLL (May 29) drew a small pullback, while FDA approval of DECNUPAZ for BPDCN (May 27) saw a positive reaction.

Key Terms

progression-free survival, median time to next treatment, adverse events, neutropenia, +4 more

8 terms

progression-free survival medical

"including an extended increase in progression-free survival in previously untreated patients"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

median time to next treatment medical

"with a demonstrated median time to next treatment of approximately eight years"

Median time to next treatment is the middle value of how long patients on a therapy go before needing a different or additional medical treatment; half of patients switch sooner and half switch later. For investors, it signals how long a drug or therapy keeps the condition under control compared with alternatives, much like knowing the average lifespan of a product’s battery helps predict replacement demand, revenue durability, and downstream treatment costs.

adverse events medical

"The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving"

Adverse events are any harmful or unwanted medical occurrences experienced by people using a drug, device, or undergoing a treatment, whether or not the problem is caused by the product. Think of them as complaints or breakdowns noticed during a trial or after a product is on the market; regulators record and investigate them. Investors care because clusters or serious adverse events can delay approvals, trigger costly studies or recalls, change labeling, and quickly alter a company’s revenue and risk profile.

neutropenia medical

"adverse events (AEs) in patients receiving the venetoclax-based combination were neutropenia, thrombocytopenia"

Neutropenia is a medical condition where the blood has an unusually low number of neutrophils, the white blood cells that act like the body’s front-line security guards against bacterial and fungal infections. For investors, it matters because neutropenia can signal safety or tolerability problems for drugs or treatments, driving clinical trial setbacks, regulatory scrutiny, additional monitoring costs, or label warnings that can influence a company’s commercial outlook and stock value. Monitoring for neutropenia is a common part of assessing medical risk and long-term financial impact.

thrombocytopenia medical

"venetoclax-based combination were neutropenia, thrombocytopenia, infusion-related reaction, anemia"

Thrombocytopenia is a medical condition marked by an abnormally low number of platelets, the blood cells that act like a patching crew to stop bleeding. It matters to investors because it can signal safety risks for drugs or procedures, affect clinical trial outcomes, trigger regulatory scrutiny, lead to additional costs or label changes, and influence a company’s stock if treatments must be halted or modified.

infusion-related reaction medical

"neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia"

An infusion-related reaction is an adverse physical response that occurs during or shortly after a medication is delivered directly into a vein, ranging from mild flushing or fever to more serious breathing or blood pressure changes. Investors care because such reactions affect a drug’s perceived safety, can change clinical trial outcomes, lead to additional testing or warning labels, and influence regulatory approval, market acceptance, and potential costs—similar to how a product’s safety recall can hurt sales and reputation.

febrile neutropenia medical

"anemia, febrile neutropenia, pneumonia and leukopenia."

A serious medical condition in which a patient develops a fever while their level of infection-fighting white blood cells, called neutrophils, is very low. Think of the body’s defenses as an army: when its front-line soldiers are depleted, even a small invader can cause major problems, leading to hospital stays, treatment delays or extra supportive care. Investors watch febrile neutropenia because its frequency and severity affect demand for therapies, clinical trial outcomes, safety labeling and healthcare costs.

leukopenia medical

"febrile neutropenia, pneumonia and leukopenia."

Leukopenia is a medical condition where a person has an unusually low number of white blood cells, the body's defenders against infection. For investors, it matters because drugs, clinical trials or side effects that cause leukopenia can raise safety concerns, delay approvals or affect market value — think of a building losing too many security guards, which increases risk and can change how investors value the asset.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.

"The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "These data continue to add to the impressive body of evidence supporting the first-line use of venetoclax-based combination regimens in broader CLL patient populations, offering patients unprecedented time to next treatment — and therefore time off treatment — after one year of fixed-duration therapy. This research advances our mission to transform care and deliver better outcomes for patients living with difficult-to-cure blood cancers."

"Venetoclax in combination with obinutuzumab has shown positive responses across several key measures compared to obinutuzumab plus chlorambucil, including an extended increase in progression-free survival in previously untreated patients with chronic lymphocytic leukemia," said Kirsten Fischer, M.D., investigator in the CLL14 study, University Hospital Cologne. "Importantly, with a demonstrated median time to next treatment of approximately eight years, the findings reflect the sustained durability of this combination treatment option with a meaningful time without CLL specific treatment for patients."

A final analysis of the Phase 3 CLL14 trial, conducted in close collaboration with the German CLL Study Group, comparing venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions, found that venetoclax plus obinutuzumab significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, providing a limited-duration treatment option for unfit patients with previously untreated CLL. The nine-year analysis demonstrated the long-term off-treatment efficacy and safety of the venetoclax plus obinutuzumab fixed-duration combination, with the median time to next treatment (TTNT) of 7.6 years.¹

After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.^1,2

CLL is one of the most common forms of leukemia in adults and is a type of cancer that can develop from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).³ Patients with CLL often experience relapsed disease, meaning the cancer has returned after previously responding to treatment, while others experience refractory disease when the cancer stops responding to therapy.⁴ While outcomes have improved in recent years, patients can often face long treatment durations and ongoing disease management challenges.

About the CLL14 Phase 3 Trial^2,5,6,7

The prospective, multicenter, open-label, randomized Phase 3 CLL14 trial (NCT02242942), which was conducted in close collaboration with the German CLL Study Group (GCLLSG), evaluated the efficacy and safety of a combined regimen of venetoclax and obinutuzumab (n=216) versus obinutuzumab and chlorambucil (n=216) in previously untreated patients with CLL and co-existing medical conditions (total Cumulative Illness Rating Scale [CIRS] score >6 or creatinine clearance <70 mL/min). The therapies were administered for a fixed duration of 12 months for venetoclax in combination with six cycles of obinutuzumab. The trial enrolled 432 patients, all of whom were previously untreated, according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Efficacy was based on PFS, as assessed by an independent review committee.

Key secondary endpoints were rates of MRD in peripheral blood and bone marrow and overall and complete response rates.

In patients with CLL receiving venetoclax combination therapy with obinutuzumab, the most frequently occurring Grade 3 (≥2%) adverse events (AEs) were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.^1,2

About VENCLYXTO

VENCLYXTO^® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.

VENCLYXTO (venetoclax) EU Indication and Summary of Important Safety Information

Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL):

• in combination with acalabrutinib with or without obinutuzumab
• in combination with obinutuzumab
• in combination with ibrutinib

VENCLYXTO in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

VENCLYXTO monotherapy is indicated for the treatment of CLL:

• In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
• In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor

Contraindications
Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase. Concomitant use of preparations containing St. John's wort.

Special Warnings & Precautions for Use
Tumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden, and splenomegaly in CLL. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.

Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period. Serious infections, including sepsis with fatal outcome, have been reported. Monitoring of any signs and symptoms of infection is required. Suspected infections should receive prompt treatment and dose interruption or reduction, as appropriate. Live vaccines should not be administered during treatment or thereafter until B-cell recovery.

Drug Interactions
CYP3A inhibitors: For patients requiring concomitant use with venetoclax, refer to the SmPC for recommendations for managing drug-drug interactions. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted. Grapefruit products, Seville oranges, and starfruit (carambola) should be avoided during treatment with venetoclax.

Additional agents that may alter venetoclax plasma concentrations include P-gp or BCRP inhibitors, CYP3A inducers (including St. John's wort), azithromycin and bile acid sequestrants. Concomitant use of these agents with venetoclax may require further dose adjustments and patients should be monitored closely for signs of toxicities.

Adverse Reactions
The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab, ibrutinib, or rituximab were diarrhoea, neutropenia, nausea, upper respiratory tract infection, fatigue and vomiting. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.

The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combination with obinutuzumab, ibrutinib, or rituximab were pneumonia, febrile neutropenia, sepsis, neutropenia, anaemia, diarrhoea and TLS. In the monotherapy studies, the most frequently reported serious adverse reactions (≥2%) were pneumonia and febrile neutropenia.

The most commonly occurring adverse reactions (≥20%) of any grade in patients treated with venetoclax in combination with acalabrutinib were infections, neutropenia, headache, bruising, diarrhoea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reaction (≥5%) was neutropenia.

The most commonly occurring adverse reactions of any grade (≥20%) in patients treated with venetoclax in combination with acalabrutinib and obinutuzumab were infections, neutropenia, headache, bruising, diarrhoea, nausea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reactions (≥5%) were neutropenia and thrombocytopenia.

Discontinuations, dosage reductions and dose interruptions due to adverse reactions have occurred in both venetoclax monotherapy and in combination therapy.

Special Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS at initiation and during the dose-titration phase. Venetoclax should be administered to patients with severe renal impairment (CrCl ≥15 ml/min and <30 ml/min) or end-stage renal disease (ESRD) requiring dialysis (CrCL <15ml/min) only if the benefit outweighs the risk and patients should be monitored closely for signs of toxicity due to increased risk of TLS.

For patients with severe hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended. These patients should be monitored more closely for signs of toxicity.

Women should avoid becoming pregnant while taking venetoclax and for at least 30 days after ending treatment. Therefore, women of childbearing potential must use highly effective contraceptive measures while taking venetoclax and for 30 days after stopping treatment. Venetoclax may harm the foetus when administered to a pregnant woman. Breast-feeding should be discontinued during treatment with venetoclax.

This is not a complete summary of all safety information. Refer to the prescribing information of each of the medicinal products used in combination with venetoclax for additional information for management of toxicities. See VENCLYXTO (venetoclax) SmPC at www.ema.europa.eu. Globally, prescribing information varies. Refer to the individual country product label for complete information.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Oncology

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Contacts:

Media: Anisha Bagchi Manix                     Email: anisha.manix@abbvie.com

Investors: Liz Shea Email: liz.shea@abbvie.com

_________________________________
1	Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.
2	Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
3	American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed June 2026.
4	Nastoupil L, Flowers C. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol. 2012; 9(12): S85–S92. doi:10.1016/j.cmonc.2012.09.019.
5	Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.
6	Summary of Product Characteristics for VENCLYXTO (venetoclax). Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.
7	VENCLEXTA (venetoclax) [Package Insert]. North Chicago, Ill.: AbbVie Inc

View original content:https://www.prnewswire.com/news-releases/abbvie-presents-new-data-at-eha-2026-congress-for-venclextavenclyxto-venetoclax-in-first-line-chronic-lymphocytic-leukemia-highlighting-long-term-treatment-outcomes-for-patients-nine-year-results-302798289.html

SOURCE AbbVie

FAQ

What did AbbVie (ABBV) announce at EHA 2026 about VENCLEXTA in first-line CLL?

AbbVie announced nine-year Phase 3 CLL14 data for fixed-duration VENCLEXTA (venetoclax) plus obinutuzumab in untreated CLL. According to AbbVie, the regimen showed durable off-treatment efficacy and safety following one year of therapy, based on long-term follow-up of study participants.

What are the nine-year CLL14 trial results for venetoclax plus obinutuzumab in untreated CLL (ABBV)?

The CLL14 trial’s final nine-year analysis showed venetoclax plus obinutuzumab improved key outcomes in untreated CLL. According to AbbVie, the combination provided long-term off-treatment efficacy and safety in patients with coexisting medical conditions, supporting its role as a first-line treatment option.

How long is the median time to next treatment with VENCLEXTA plus obinutuzumab in the CLL14 study?

Median time to next treatment was 7.6 years with venetoclax plus obinutuzumab in CLL14. According to AbbVie, this extended treatment-free interval followed approximately one year of fixed-duration therapy, offering patients a meaningful period without CLL-specific treatment after first-line therapy.

How did venetoclax plus obinutuzumab affect progression-free survival versus chlorambucil in CLL14 (ABBV)?

Venetoclax plus obinutuzumab achieved median progression-free survival of 6.4 years versus 3.2 years with chlorambucil plus obinutuzumab. According to AbbVie, the hazard ratio was 0.50 (95% CI 0.39-0.63, p<0.001) after a median follow-up of 9.2 years in previously untreated CLL patients.

What Grade 3 or higher adverse events were seen with VENCLEXTA-based therapy in the CLL14 trial?

Common Grade 3 or higher adverse events included neutropenia and thrombocytopenia with venetoclax plus obinutuzumab. According to AbbVie, other frequent serious events (≥2%) were infusion-related reactions, anemia, febrile neutropenia, pneumonia, and leukopenia in patients receiving the venetoclax-based combination.

Why are the CLL14 nine-year results important for chronic lymphocytic leukemia treatment and ABBV investors?

The CLL14 nine-year data highlight a fixed-duration regimen with multi-year treatment-free intervals in CLL. According to AbbVie, prolonged progression-free survival and 7.6-year median time to next treatment may influence first-line standards of care in difficult-to-cure blood cancers like CLL.